Last reviewed · How we verify
recomon (Epoetin Beta)
Recomon is a recombinant erythropoietin (EPO) that stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells to increase red blood cell production.
Recomon is a recombinant erythropoietin (EPO) that stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells to increase red blood cell production. Used for Anemia associated with chronic kidney disease, Anemia in patients with cancer receiving chemotherapy, Anemia in patients undergoing major surgery.
At a glance
| Generic name | recomon (Epoetin Beta) |
|---|---|
| Sponsor | JW Pharmaceutical |
| Drug class | Erythropoiesis-stimulating agent (ESA) |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Epoetin beta is a glycoprotein hormone produced through recombinant DNA technology that mimics endogenous erythropoietin. It binds to EPO receptors on erythroid progenitor cells in the bone marrow, promoting their proliferation, differentiation, and maturation into mature red blood cells. This increases hemoglobin levels and oxygen-carrying capacity in patients with anemia.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia in patients with cancer receiving chemotherapy
- Anemia in patients undergoing major surgery
Common side effects
- Hypertension
- Headache
- Thrombosis/thromboembolic events
- Injection site reactions
- Flu-like symptoms
- Pure red cell aplasia (rare)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- recomon (Epoetin Beta) CI brief — competitive landscape report
- recomon (Epoetin Beta) updates RSS · CI watch RSS
- JW Pharmaceutical portfolio CI